In Vitro Activity of Garenoxacin against Streptococcus pneumoniae Mutants with Characterized Resistance Mechanisms-Reference-Cited by-同舟云学术

In Vitro Activity of Garenoxacin against Streptococcus pneumoniae Mutants with Characterized Resistance Mechanisms

Published:2009-08 Issue:8 Volume:53 Page:3572-3575
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Yamamoto Kazuko¹,Yanagihara Katsunori²,Sugahara Kazuyuki²,Imamura Yoshifumi¹,Seki Masafumi¹,Izumikawa Koichi¹,Kakeya Hiroshi¹,Yamamoto Yoshihiro¹,Hirakata Yoichi³,Kamihira Shimeru²,Kohno Shigeru¹

Affiliation:

1. Department of Molecular Microbiology and Immunology

2. Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Japan

3. Department of Infection Control and Laboratory Diagnostics, Internal Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan

Abstract

ABSTRACT We evaluated the potency of garenoxacin in selecting resistant Streptococcus pneumoniae mutants by determining its mutant prevention concentration, using strains with and without topoisomerase gene mutations, and compared its potency to that of other quinolones. Garenoxacin had a significantly greater potency against pneumococci, including strains containing topoisomerase mutations. Genetic analysis of the S. pneumoniae mutants created by garenoxacin revealed that the gyrA gene was a primary target of garenoxacin.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00176-09

Reference22 articles.

1. Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae : Contributions of Type II Topoisomerase Mutations and Efflux to Levels of Resistance

2. Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae

3. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med.341:233-239.

4. Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001

5. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. Azavedo, P. Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med.346:747-750.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions;Antimicrobial Agents and Chemotherapy;2018-04

2. Traceless Directing Group Assisted Cobalt-Catalyzed C−H Carbonylation of Benzylamines;Advanced Synthesis & Catalysis;2017-09-20

3. Molecular Investigation of Quinolone Resistance of Quinolone Resistance-Determining Region in Streptococcus pneumoniae Strains Isolated from Iran Using Polymerase Chain Reaction–Restriction Fragment Length Polymorphism Method;Osong Public Health and Research Perspectives;2014-10

4. Resistance to different generations of quinolones in Streptococcus pneumoniae strains isolated from hospitals in Shiraz;Comparative Clinical Pathology;2014-05-10

5. Resistance of M. leprae to Quinolones: A Question of Relativity?;PLoS Neglected Tropical Diseases;2013-11-14